23,313 Illumina, Inc. $ILMN Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 64.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,778 shares of the life sciences company’s stock after selling 23,313 shares during the period. Yousif Capital Management LLC’s holdings in Illumina were worth $3,497,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ILMN. BlackRock Inc. bought a new position in Illumina during the 2nd quarter worth $3,374,423,000. Plato Investment Management Ltd acquired a new position in Illumina during the 2nd quarter worth about $948,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Illumina in the 2nd quarter valued at about $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina in the 2nd quarter valued at about $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Illumina in the 2nd quarter valued at about $6,711,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Zacks Research cut Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 1st. UBS Group raised Illumina from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $135.00 to $260.00 in a research note on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft cut Illumina to a “hold” rating in a report on Wednesday, August 5th. Stephens reissued an “equal weight” rating and set a $275.00 target price on shares of Illumina in a research report on Friday. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $205.00 to $300.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Ten equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Illumina currently has an average rating of “Hold” and an average price target of $234.41.

Insider Activity

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the transaction, the director directly owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is owned by corporate insiders.

Illumina Stock Performance

Shares of ILMN opened at $271.04 on Tuesday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $40.93 billion, a P/E ratio of 52.31, a price-to-earnings-growth ratio of 3.82 and a beta of 1.41. The firm’s fifty day simple moving average is $241.80 and its two-hundred day simple moving average is $173.01. Illumina, Inc. has a 12 month low of $94.00 and a 12 month high of $309.35.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the business posted $1.19 EPS. The business’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.